Vecuronium
- Atc Codes:M03AC03
- CAS Codes:50700-72-6
- PHARMGKB ID:50700-72-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Norcuron; Belgium: Norcuron; Cyprus: Norcuron; Czech Republic: Norcuron; Finland: Norcuron; France: Norcuron; Germany: Norcuron, Vecuronium; Greece: Norcuron; Ireland: Norcuron; Italy: Norcuron; Luxembourg: Norcuron; Netherlands: Norcuron; Poland: Norcuron; Portugal: Norcuron; Romania: Norcuron; Slovakia: Norcuron; Slovenia: Norcuron; Spain: Norcurón, Vecuronio; Sweden: Norcuron; UK: Norcuron.
North America
Canada: Vecuronium; USA: Vecuronium.
Latin America
Argentina: Galarén, Gobbicuronio, Rivecrum, Vecural, Vecurón, Vecuronio; Brazil: Norcuron, Vecuron; Mexico: Bromivec, Nodescrón, Norcurón, Vecuronio.
Asia
Japan: Musculax, Muscurate.
Drug combinations
Chemistry
Vecuronium Bromide: C~34~H~57~BrN~2~O~4~. Mw: 637.73. (1) Piperidinium, 1-[(2β,3α,5α,16β,17β)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, bromide; (2) 1-(3α,17β-Dihydroxy-2β-piperidino-5α-androstan-16β,5α-yl)-1-methylpiperidinium bromide, diacetate. CAS-50700-72-6 (1984).
Pharmacologic Category
Neuromuscular Blocking Agents, Nondepolarizing. (ATC-Code: M03AC03).
Mechanism of action
Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization.
Therapeutic use
Adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery. Facilitation of mechanical ventilation.
Pregnancy and lactiation implications
Use in cesarean section reported. Excretion in breast milk unknown (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to vecuronium or any component of the formulation.
Warnings and precautions
Does not counteract bradycardia produced by anesthetics/vagal stimulation. Cross-sensitivity with other neuromuscular-blocking agents may occur (use extreme caution in previous anaphylactic reactions). Resistance may occur in burn patients (>30% of body) for period of 5-70 days postinjury. Conditions which may antagonize neuromuscular blockade (alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus) may result in antagonism of neuromuscular blockade. Conditions which may potentiate neuromuscular blockade (electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure) may result in potentiation of neuromuscular blockade. Use with caution in hepatic or renal impairment, and in the elderly. Resistance may occur in immobilized patients. Vecuronium produces minimal, if any, histamine release. Does not relieve pain or produce sedation.